


We claim:


1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof.


2. The compound according to Claim 1 of formula (II)



(II)


or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 2 of formula (II)



(II)


4. The compound according to Claim 1 of formula (III)



(III)

or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 4 of formula (III)



(III)

6. The compound or salt according to Claim 2 which is is a [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate besylate.
7. The compound or salt according to Claim 2 which is is a [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate hemi-edisylate hydrate.
8. The compound or salt according to Claim 4 which is is a [(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate besylate.
9. The compound or salt according to Claim 4 which is is a [(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate hemi-edisylate hydrate.

10. The compound or salt according to either Claim 2 or Claim 6 which is crystalline [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate besylate.
11. The compound or salt according to Claim 10 which is crystalline [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate besylate characterized by a X-ray powder diffraction pattern having characteristic peaks using CuK α radiation, in $2\theta \pm 0.2^\circ$, occurring at 21.5° in combination with one or more peaks selected from the group consisting of 12.4° , 17.3° , and 15.8° .
12. The compound or salt according to either Claim 2 or Claim 7 which is crystalline [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate hemi-edisylate hydrate.
13. The compound or salt according to Claim 12 which is [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate hemi-edisylate hydrate characterized by a X-ray powder diffraction pattern having characteristic peaks using CuK α radiation, in $2\theta \pm 0.2^\circ$, occurring at 18.5° in combination with one or more peaks selected from the group consisting of 21.5° , 16.7° , and 15.2° .
14. The compound or salt according to either Claim 4 or Claim 8 which is crystalline [(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate besylate.
15. The compound or salt according to either Claim 4 or Claim 9 which is crystalline [(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate hemi-edisylate hydrate.

16. A pharmaceutical composition comprising a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.
17. The pharmaceutical composition according to Claim 16 comprising one or more other therapeutic agents.
18. A method of treating urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, or gliomas comprising administering a therapeutically effective amount of a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
19. The method according to Claim 18 wherein the cancer is colorectal cancer, breast cancer, lung cancer, ovarian cancer, or gastric cancer.
20. The method according to either Claim 18 or Claim 19 wherein the cancer is breast cancer.
21. A method of treating urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, pancreatic cancer, cervical cancers, prostate cancer, haematological cancers, sarcomas, skin cancers, or gliomas in a patient, comprising testing for the presence of at least one loss of function mutation in the *ARID1A*, *KMT2C*, *KMT2D* or *RB1* gene in a biological sample from the patient and administering a therapeutically effective amount of a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof to the patient if the sample tests positive for the loss of function mutation.
22. A method of treating urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian

- cancer, gastric cancer, hepatobiliary cancer, pancreatic cancer, cervical cancers, prostate cancer, haematological cancers, sarcomas, skin cancers, or gliomas in a patient, comprising administering a therapeutically effective amount of a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof to the patient provided that a biological sample from the patient contains at least one loss of function mutation in the *ARID1A*, *KMT2C*, *KMT2D* or *RBI* gene.
23. A method of treating urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, pancreatic cancer, cervical cancers, prostate cancer, haematological cancers, sarcomas, skin cancer, or gliomas in a patient, comprising administering a therapeutically effective amount of a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof to the patient provided that the patient is selected for treatment if a biological sample from the patient tests positive for at least one loss of function mutation in the *ARID1A*, *KMT2C*, *KMT2D* or *RBI* gene.
24. The method according to any one of Claims 18 to 23 wherein the compound or salt is [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate or a pharmaceutically acceptable salt thereof.
25. The method according to any one of Claims 18 to 23 wherein the compound or salt is [(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(3-isopropyl-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate or a pharmaceutically acceptable salt thereof.
26. The method according to any one of Claims 18 to 25 wherein the salt is a besylate salt.
27. The method according to any one of Claims 18 to 25 wherein the salt is a hemi-edisylate hydrate salt.

28. The method according to any one of Claims 21 to 27 wherein the biological sample is a tumor sample and the sample is assayed by genomic/DNA sequencing.
29. The method according to any one of Claims 21 to 28 wherein the sample is obtained from the patient prior to a first administration of the compound or salt to the patient.
30. The method according to any one of Claims 21 to 29 wherein the gene is the *ARID1A* gene.
31. The method according to any one of Claims 21 to 29 wherein the gene is the *KMT2C* gene.
32. The method according to any one of Claims 21 to 29 wherein the gene is the *KMT2D* gene.
33. The method according to any one of Claims 21 to 29 wherein the gene is the *RB1* gene.
34. A compound or salt thereof according to any one of Claims 1 to 15, for use in therapy.
35. A compound or salt thereof, according to any one of Claims 1 to 15, for use in the treatment of urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, pancreatic cancer, cervical cancers, prostate cancer, haematological cancers, sarcomas, skin cancers, or gliomas.
36. The compound or salt for use according to Claim 35 wherein the cancer is colorectal cancer, breast cancer, lung cancer, ovarian cancer, or gastric cancer.
37. The compound or salt for use according to either Claim 35 or 36 wherein the cancer is breast cancer.

38. The compound or salt thereof for use according to any one of Claims 34 to 37, also comprising performing an *in vitro* assay using a biological sample from the patient, determining the presence of at least one inactivating mutation in the *ARID1A*, *KMT2C*, *KMT2D* and *RBI* genes, and administering a therapeutically effective amount of the compound or salt thereof to the patient if at least one inactivating mutation in any of genes is present.
39. The compound or salt thereof for use according to Claim 38 wherein the biological sample is a tumor sample and the sample is assayed by genomic/DNA sequencing.
40. The compound or salt thereof for use according to either Claims 38 or 39 wherein the sample is obtained from the patient prior to the first administration of the compound or the salt thereof to the patient.
41. The compound for salt thereof for use according to any one of Claims 34 to 40 wherein a patient is selected for treatment by having at least one inactivating mutation in the *ARID1A* gene.
42. The compound or salt thereof for use according to any one of Claims 34 to 40 wherein a patient is selected for treatment by having at least one inactivating mutation in the *KMT2C* gene.
43. The compound or salt thereof for use according to any one of Claims 34 to 40 wherein a patient is selected for treatment by having at least one inactivating mutation in the *KMT2D* gene.
44. The compound or salt thereof for use according to to any one of Claims 34 to 40 wherein a patient is selected for treatment by having at least one inactivating mutation in the *RBI* gene.
45. The compound or salt thereof for use according to any one of Clams 34 to 44 wherein the compound of salt thereof is administered to the patient at a dose of about 1 mg to 2 g.

46. A use of a compound according to any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a urothelial cancer, uterine cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, hepatobiliary cancer, pancreatic cancer, cervical cancers, prostate cancer, haematological cancers, sarcomas, skin cancers, or gliomas.
47. The use according to Claim 46 wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, lung cancer, ovarian cancer, or gastric cancer.
48. The use according to any one of Claims 46 or 47, also comprising performing an *in vitro* assay using a biological sample from the patient, determining the presence of at least one inactivating mutation in the *ARID1A*, *KMT2C*, *KMT2D* and *RBI* genes, and administering a therapeutically effective amount of the compound or salt thereof to the patient if at least one inactivating mutation in any of the genes is present.
49. The use according to Claim 48 wherein the biological sample is a tumor sample and the sample is assayed by genomic/DNA sequencing.
50. The use according to any one of Claims 46 to 49 wherein the sample is obtained from the patient prior to the first administration of the compound or the salt thereof to the patient.
51. The use according to any one of Claims 46 to 50 wherein a patient is selected for having at least one inactivating mutation in the *ARID1A* gene.
52. The use according to any one of Claims 46 to 50 wherein a patient is selected for having at least one inactivating mutation in the *KMT2C* gene.
53. The use according to any one of Claims 46 to 50 wherein a patient is selected for having at least one inactivating mutation in the *KMT2D* gene.

54. The use according to any one of Claims 46 to 50 wherein a patient is selected for having at least one inactivating mutation in the *RBI* gene.
55. The use according to any one of Claims 46 to 50 wherein the compound of salt thereof is administered to the patient at a dose of about 1 mg to 2 g.